Empagliflozin, Linagliptin

Indications

Empagliflozin, Linagliptin is used for: Empagliflozin
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Linagliptin
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise[FDA Label]. It should not be used to treat type I diabetes or in diabetic ketoacidosis[FDA Label].

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Empagliflozin, Linagliptin :

Mechanism of Action

Empagliflozin
Empagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
Linagliptin
Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)[FDA Label][A37050]. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells[FDA Label]. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose[FDA Label][A37050].